Program
sacituzumab drozuntecan
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by DualityBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| DualityBio | 22 open or running | phase 2since Jun 14, 2022 | Jun 14, 2022 | Aug 13, 2027phase 2 · NCT05438329 |
Also a collaborator on its studies: BioNTech.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 14, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05438329 · 1,123 enrolled · United States, China, Puerto Rico
- Apr 9, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089 · 750 planned · United States, Australia, China and more
- Jul 10, 2025Named sacituzumab drozuntecanINNProposed as its International Nonproprietary Name in WHO's List 133
Ahead
- Aug 13, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT05438329
- Jun 30, 2030Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06953089Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more | 2 | Recruiting | Jun 30, 2030 | 750 |
| NCT05438329Advanced Solid Tumor · United States, China, Puerto Rico | 2 | Active, not recruiting | Aug 13, 2027 | 1,123 |
How it is read
Names in the registry
- “DB-1305/BNT325”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.